Philip Arlen, M.D.
President and Chief Executive Officer
Professional Overview
Dr. Philip Arlen is a respected leader in the biotechnology and oncology fields, with extensive experience in both clinical research and executive leadership roles. As the President and Chief Executive Officer of Precision Biologics, Inc., he oversees the company's strategic direction and operations, driving the development of innovative cancer treatments. Additionally, he serves as the Chair of the Intramural Research Program's Institutional Review Board (IRB) at the National Institutes of Health (NIH), where he provides oversight and guidance on critical medical research projects.
Experience Summary
Current Role
As the President and Chief Executive Officer of Precision Biologics, Inc., Dr. Arlen is responsible for the overall management and strategic direction of the company. He has led the organization in advancing its pipeline of novel cancer immunotherapies, fostering collaborations with leading research institutions and biopharmaceutical partners. Under his leadership, Precision Biologics has made significant strides in bringing promising treatment options to patients with unmet medical needs.
In his role as the Chair of the NIH Intramural Research Program's IRB, Dr. Arlen provides invaluable expertise and oversight, ensuring the ethical conduct and safety of critical medical research projects undertaken by the National Institutes of Health.
Career Progression
Prior to his current positions, Dr. Arlen served as the President and Chief Executive Officer of Neogenix Oncology Inc., where he led the company's efforts in developing innovative cancer therapies. He also has a long-standing association with the National Cancer Institute (NCI), having held various leadership roles, including Director of the Clinical Research Group in the Laboratory of Tumor Immunology and Biology, and Chair of the Institutional Review Board for the NCI's intramural research program.
Dr. Arlen's extensive experience in both clinical research and executive management has enabled him to drive meaningful advancements in the field of oncology and make significant contributions to the biopharmaceutical industry.
Academic Background
Dr. Arlen holds a medical degree and has completed his residency and fellowship training in medical oncology. He has maintained a strong commitment to academic and research pursuits, contributing to numerous peer-reviewed publications and serving as a respected thought leader in the field.
Areas of Expertise
- Oncology drug development
- Immunotherapy and cancer research
- Clinical trial design and management
- Institutional review board oversight
- Strategic leadership and executive management
Professional Impact
Under Dr. Arlen's leadership, Precision Biologics has made significant progress in advancing its pipeline of innovative cancer immunotherapies, with several promising candidates in various stages of clinical development. His work on the NIH Intramural Research Program's IRB has helped ensure the ethical and safe conduct of critical medical research projects, ultimately benefiting patients and advancing the scientific understanding of complex diseases.
Conclusion
With his extensive expertise in oncology, clinical research, and biopharmaceutical leadership, Dr. Philip Arlen is well-positioned to continue driving meaningful advancements in the field of cancer treatment and research. His strategic vision, coupled with his commitment to ethical practices and patient-centric approaches, make him a valuable asset to both Precision Biologics and the broader medical research community.
